If you take a compounded GLP-1 — or you've been weighing it because the brand-name versions cost more than $500 a month — there's a federal deadline you should know about. On April 30, 2026, the FDA formally proposed removing semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that outsourcing facilities are allowed to compound. The public comment period on that proposal closes June 29, 2026. After it does, the agency is expected to move toward a final rule that would close the largest remaining channel for affordable compounded GLP-1s.
This is the latest and most decisive step in a regulatory sequence that's been tightening for more than a year. It's also widely misunderstood — partly because "FDA bans compounded semaglutide" headlines compress a slow, multi-stage administrative process into a single scary sentence. This article lays out exactly what's on the table, what it changes for patients, and how to submit a comment if you want your perspective on the record before the window shuts.
The short version: The shortages that made widespread GLP-1 compounding legal are over. The FDA's April 2026 proposal would remove semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list. Public comment closes June 29, 2026; a final rule is expected around Q3 2026. Nothing is illegal today that wasn't yesterday — but the door is closing, and June 29 is the public's last scheduled chance to weigh in.
How we got here: the shortage was the whole game
Compounded GLP-1 access was never really about a special carve-out for these drugs. It was about shortage. Federal law lets compounders prepare copies of an FDA-approved drug while that drug is on the official shortage list — and from 2022 through early 2025, the brand-name GLP-1s were chronically short. That single fact is what created the entire compounded-GLP-1 economy: telehealth clinics, outsourcing-facility supply, and prices a fraction of the branded versions.
Then the shortages ended. The FDA determined the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved on February 21, 2025. The moment a drug leaves the shortage list, the legal basis for compounding copies of it largely disappears, and the agency's temporary enforcement discretion winds down on a set schedule. By spring 2025, those grace periods had lapsed for 503A pharmacies and, shortly after, for 503B outsourcing facilities — and a federal court declined to block the FDA in Outsourcing Facilities Association v. FDA. We covered that shift in detail in our explainer on whether peptides are legal in 2026.
The April 30, 2026 proposal is the cleanup step. Even with the shortages over, outsourcing facilities retained a narrow pathway to compound from bulk semaglutide and tirzepatide because those substances still sat on the 503B bulks list. The new proposal removes them — closing that pathway deliberately rather than letting it persist in a gray zone.
What the 503B bulks list actually is
To understand what's being voted on, it helps to know the two kinds of compounders, because the proposal hits them differently. This is the same distinction our compounded GLP-1 legality checker walks you through interactively.
A 503A pharmacy compounds for one identified patient who has a prescription. A 503B outsourcing facility can make larger batches without a patient-specific prescription — but only from substances the FDA has placed on the 503B bulks list after determining there's a clinical need. Most of the affordable, at-scale compounded GLP-1 supply has flowed through 503B facilities. Removing semaglutide and tirzepatide from the bulks list is aimed squarely at that channel.
The 503A pathway isn't erased by this proposal, but it's narrow. Now that the brand drugs are available, a 503A pharmacy generally can't compound something that's "essentially a copy" of Wegovy, Ozempic, Zepbound, or Mounjaro. It can only compound when there's a genuine, documented clinical reason — a dose that isn't commercially made, or a verified allergy to an inactive ingredient. "It's cheaper" doesn't qualify.
The rules are changing in the next 90 days
Get a plain-English email the moment compounded GLP-1 legality shifts — so you're never caught buying from a channel that just closed.
Free forever. Unsubscribe anytime.
What this means for patients right now
The most important thing to understand: June 29 is a comment deadline, not a ban date. A proposed rule is a draft. Until the FDA publishes a final rule — expected around Q3 2026 — the current rules still apply. Concretely, that means:
- Today: 503B facilities can still compound from bulk semaglutide and tirzepatide, and 503A pharmacies can still make patient-specific preparations where a real clinical need exists. Many telehealth platforms are still filling orders.
- If your supply runs through a 503B facility: plan for it to change. That's the channel the proposal is built to close.
- If you're shopping on price alone: be careful. As legitimate compounded supply tightens, "too good to be true" pricing increasingly signals an unregulated, research-chemical, or overseas source rather than a licensed pharmacy. Our guide to sourcing peptides safely covers what to verify.
It's also worth knowing why the FDA is moving. Beyond the shortage technicality, the agency has pointed to safety: it had received hundreds of adverse-event reports tied to compounded GLP-1s — 455-plus for semaglutide and 320-plus for tirzepatide as of early 2025 — many involving dosing errors when patients drew incorrect amounts from multi-dose vials. If you do use a compounded vial, our reconstitution calculator and our explainer on the GLP-1 appetite cycle can help you avoid the most common mistakes. For the bigger picture on how these drugs work, see our guide to GLP-1 peptides.
How to submit a comment before June 29
Public comment is the one formal point where patients, prescribers, and pharmacists can put their experience directly into the federal record. The FDA is legally required to review and respond to substantive comments during rulemaking — though it weighs the substance of comments, not the raw count, so a specific, firsthand account carries more weight than a form letter. Here's how to do it:
One honest caveat: commenting is a real civic lever, but it isn't a vote. The FDA can finalize the rule regardless of how many comments come in. What comments do reliably affect is the record the agency must address and the basis for any later legal challenge. Treat it as making your case, not casting a ballot.
What happens after the deadline
Once the comment window closes, the FDA reviews submissions and moves toward a final rule. Analysts broadly expect the bulks-list exclusion to be finalized around the third quarter of 2026. When it is, the 503B channel for compounded semaglutide and tirzepatide effectively closes, and the realistic landscape narrows to three options: brand-name drugs (now more available, but expensive), genuinely individualized 503A compounding (legal but narrow), and the unregulated gray market (cheap and risky). This is the same fork the Peptide Sciences shutdown previewed for the broader peptide market last spring — when a major supply source disappears, demand doesn't vanish, it relocates.
This GLP-1 proposal is also separate from — but rhymes with — the FDA's broader 2026 reconsideration of peptide compounding rules. Both reflect an agency trying to draw a sharper line between regulated, physician-supervised access and an unregulated parallel market it can't easily control.
The bottom line
The compounded-GLP-1 era that the shortages created is winding down on a published schedule, and June 29, 2026 is the public's last formal checkpoint before the most consequential step is finalized. If you rely on compounded semaglutide or tirzepatide, two things are worth doing this month: verify where your specific supply stands (channel and legality), and, if you have a stake in the outcome, submit a comment before the window closes. Neither guarantees a particular result — but both beat being surprised when a channel you depend on quietly shuts.
Not sure whether your medication and provider are still on solid legal ground? Run them through our free compounded GLP-1 legality checker — it maps your situation to the current 503A/503B rules and this exact proposal.
References
- U.S. Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." Press announcement, April 30, 2026. fda.gov
- Federal Register. "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act." May 1, 2026. federalregister.gov
- U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." fda.gov
- U.S. Food and Drug Administration. "Declaratory Order: Resolution of Shortages of Tirzepatide Injection." fda.gov
- National Community Pharmacists Association. "FDA ends compounding discretion for tirzepatide, maintains discretion for semaglutide." March 2025. ncpa.org
- Federal Food, Drug, and Cosmetic Act, Sections 503A and 503B. Compounding of Human Drug Products.
Frequently asked questions
When does the FDA comment period on compounded GLP-1s close?
June 29, 2026. That's the deadline to submit comments on the FDA's proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list. Comments are filed through Regulations.gov and become part of the public record.
Does this mean compounded semaglutide is illegal now?
No. June 29 is a comment deadline on a proposed rule, not a ban date. As of now, 503B facilities can still compound from bulk semaglutide and tirzepatide, and 503A pharmacies can still make patient-specific preparations with a documented clinical need. A final rule is expected around Q3 2026.
What is the 503B bulks list?
It's the FDA's list of bulk drug substances that registered outsourcing facilities may compound without a patient-specific prescription, based on a finding of clinical need. Removing the GLP-1s from it would end large-scale outsourcing-facility compounding of those drugs.
Can a patient actually submit a comment?
Yes. Anyone can comment through Regulations.gov before the deadline. The FDA must consider substantive comments during rulemaking, though it weighs their substance rather than counting them like votes. A specific, firsthand account is more useful than a form letter.
Will this affect 503A patient-specific prescriptions?
The proposal targets the 503B bulks pathway. 503A compounding remains legal, but it's narrow now that the brand drugs are available — a pharmacy generally can't compound an "essentially a copy" version, only a genuinely individualized preparation with a documented clinical reason.